Nu Skin Enterprises Inc - A (NUS) 13F Investor Activity Report (Q2 2026)

NUS ranks #3480 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

164 institutions disclose a position in NUS, but none treat it as a major bet — even Coppell Advisory Solutions LLC, its most concentrated holder, allocates just 0.9% of its own portfolio to it.

Ken Griffin has added to its NUS position for two straight quarters, increasing it by $3.4M to reach $3.6M today.

BlackRock has trimmed its NUS position for two straight quarters, cutting it by $18.7M while still holding $22.8M.

NUS is down 2.6% today, but institutions show net buying of $13.1M this quarter — a divergence between today's price move and the underlying institutional flow.

NUS reported a net loss of $216.4M over the trailing twelve months.

• Not yet profitable — net loss of $216.4M over the trailing twelve months
• Revenue declined 15.4% year over year
• Net income declined year over year, from $100.8M to -$216.4M
• Generated $80.3M in positive operating cash flow
• Current ratio of 2.08x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.75x equity — within a conventional range